Tiziana Life Sciences announced that Dr. Howard Weiner will present positive data from a study of intranasal anti-CD3 monoclonal antibody, mAb, in an animal model of Alzheimer’s disease on April 1, 2023 at the AD/PD 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders in Gothenburg, Sweden. "With the FDA approvals of aducanumab and lecanemab, there is a renewed focus on effective Alzheimer’s disease treatments and we have the potential to be a novel, first in class neuroinflammatory modulator," commented Gabriele Cerrone, Executive Chairman and interim Chief Executive Officer of Tiziana. "Our unique intranasal approach has the potential that does not target beta-amyloid or other proteins, but focuses on the neuroinflammatory process itself, which may be complementary or synergistic with existing treatments."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TLSA:
- Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer’s Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Disorders Conference in Sweden
- Tiziana intends to start Phase 2 trial of intranasal foralumab in Q3
- Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
- Tiziana Life Sciences announces purchase of common shares by chairman
- Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO